Researchers at the Beijing Biotechnology Institute in Beijing, China, who conducted the study, say the vaccine produces a rapid immune response to the deadly disease.
The test was done on 109 healthy adults aged 18 to 60 and showed promising results after 28 days – the final results to be evaluated in six months.
New research published in the medical journal The Lancet hails this discovery as “an important step.”
“The trial demonstrates that a single dose of the new vectorized COVID-19 adenovirus vaccine (Ad5-nCoV) produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation.” ‘Said Professor Wei Chen of said the Beijing Biotechnology Institute.
“These results represent an important step.
“The challenges in developing a COVD-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19.
“This result shows a promising vision for the development of COVID-19 vaccines, but we are still far from this vaccine accessible to all.”
More trials are needed to determine if the immune response it triggers can effectively protect against SARS-CoV-2 infection, but the signs are promising.
Explanation of the coronavirus
Creating an effective vaccine to defeat the killer virus is seen as the long-term solution to the COVID-19 pandemic.
Currently, more than 100 COVID-19 candidate vaccines are being developed worldwide.
The new “COVID-19 Ad5 vector vaccine” is the first to be tested in humans.
It uses a weakened common cold virus to provide genetic material that makes coronavirus inside human cells.